January 21, 2004

Hemangiomas and Other Congenital Malformations in Infants Exposed to Antiretroviral Therapy In Utero

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(3):305. doi:10.1001/jama.291.3.305

To the Editor: Pregnancy is not an indication for discontinuing or delaying combined antiretroviral therapy (CART) in women with human immunodeficiency virus (HIV) infection, but concerns remain about potential adverse effects for the infant.1,2 Prior small case series have suggested an increased risk for hemangioma.3,4 We assessed the risk of hemangioma and other congenital malformations in a somewhat larger cohort of infants exposed to CART in utero, as well as in a comparison cohort.

First Page Preview View Large
First page PDF preview
First page PDF preview